Ebastine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Ebastine: From Allergic Rhinitis to Coronary Artery Disease
One-Sentence Summary
Ebastine is a second-generation H1-antihistamine, originally used for allergic rhinitis, vasomotor rhinitis and idiopathic urticaria. The TxGNN model predicts it may be effective for coronary artery disease, but there are currently no clinical trials and no publications supporting this direction, so the prediction rests on the computational model alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Allergic rhinitis, vasomotor rhinitis, idiopathic urticaria |
| Predicted New Indication | Coronary artery disease |
| TxGNN Prediction Score | 0.9918 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (at least 20) – CDSCO approval status is not included in this data |
| Number of Listed Products | at least 20 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, ebastine belongs to the class of second-generation H1-antihistamines. Its efficacy in allergic rhinitis and urticaria is established, and a speculative mechanistic link to coronary artery disease may exist through histamine and mast cell signalling in atherosclerosis and coronary vasospasm.
This link is not supported by any trial or publication in the data compiled for this report. The high TxGNN score (0.9918) is a computational prediction only and should not be read as evidence of efficacy.
Other predictions for ebastine, such as myocardial ischemia, also have no clinical support. The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for the lead prediction (coronary artery disease).
India Market Information
Ebastine is marketed in India with 20 valid single-ingredient registrations and no cancelled ones. The compiled data do not include approved indication text for these products. Main registrations:
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| Registration No. 75380 | Eba P 10mg/10mg Tablet | Strip of 10 tablets | Not specified |
| Registration No. 80516 | Ebahist 10mg Tablet | Strip of 10 tablets | Not specified |
| Registration No. 81024 | Elbast 20mg Tablet | Strip of 10 tablets | Not specified |
| Registration No. 74955 | Ebast 5mg Tablet DT | Strip of 10 tablet DT | Not specified |
| Registration No. 72774 | Ebast Suspension | Bottle of 60 ml suspension | Not specified |
Safety Considerations
Please refer to the package insert for safety information.
Note: ebastine’s drug class has a history of QT-related concerns (for example terfenadine), although ebastine’s own risk is considered low at standard doses. This matters if the drug is considered for patients with cardiac disease.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction for coronary artery disease is supported only by the TxGNN model score, with no clinical trials or publications. Safety data from the package insert are also missing, and cardiac safety in a coronary population would need specific attention.
To proceed, the following is needed:
- Mechanism of action data for ebastine
- Preclinical or mechanistic studies linking histamine/H1 signalling to coronary disease
- Package insert warnings and contraindications from India
- Cardiac safety assessment, including QT effects
- Any observational or clinical data on ebastine in cardiovascular outcomes
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.